0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
RSS Email Alerts
Please Wait... Processing your request... Please Wait.

JAMA Oncology | 
Editorial |  FREE ONLINE FIRST
Tara C. Gangadhar, MD; Lynn M. Schuchter, MD
JAMA Oncol. Published online May 21, 2015. doi:10.1001/jamaoncol.2015.1237

JAMA Oncology | 
Original Investigation |  Open Access ONLINE FIRST
James Larkin, MD, PhD; Christopher D. Lao, MD, MPH; Walter J. Urba, MD, PhD; et al.
JAMA Oncol. Published online May 21, 2015. doi:10.1001/jamaoncol.2015.1184
Includes: Supplemental Content

JAMA | 
Viewpoint |  FREE ONLINE FIRST
Xiaoliang Sunney Xie, PhD
JAMA. Published online May 14, 2015. doi:10.1001/jama.2015.5533

JAMA Oncology | 
Research Letter |  Open Access ONLINE FIRST
Helena A. Yu, MD; Shaozhou K. Tian, MD; Alexander E. Drilon, MD; et al.
JAMA Oncol. Published online May 07, 2015. doi:10.1001/jamaoncol.2015.1066

JAMA Oncology | 
Review |  FREE ONLINE FIRST
Chadi Nabhan, MD; Gordana Raca, MD, PhD; Y. Lynn Wang, MD, PhD
JAMA Oncol. Published online May 07, 2015. doi:10.1001/jamaoncol.2015.0779

JAMA Neurology | 
Clinical Implications of Basic Neuroscience Research | 
Oren J. Zarnett, BSc; Arjun Sahgal, MD; Jessica Gosio; et al.
JAMA Neurol. 2015;72(5):589-596. doi:10.1001/jamaneurol.2014.3739.
Includes: Supplemental Content

JAMA Oncology | 
Observation |  FREE
Vivek Subbiah, MD; Pete Anderson, MD, PhD; Eric Rohren, MD, PhD
JAMA Oncol. 2015;1(2):253-255. doi:10.1001/jamaoncol.2014.289.

JAMA Oncology | 
Editorial |  FREE
Daniel Morgensztern, MD; Katerina Politi, PhD; Roy S. Herbst, MD, PhD
JAMA Oncol. 2015;1(2):146-148. doi:10.1001/jamaoncol.2014.278.

JAMA Oncology | 
Brief Report |  FREE
Eliezer M. Van Allen, MD; Vivian W. Y. Lui, PhD; Ann Marie Egloff, PhD; et al.
JAMA Oncol. 2015;1(2):238-244. doi:10.1001/jamaoncol.2015.34.
Includes: Supplemental Content

JAMA Oncology | 
Viewpoint |  FREE
Carlo Gambacorti-Passerini, MD; Rocco Piazza, MD, PhD
JAMA Oncol. 2015;1(2):143-144. doi:10.1001/jamaoncol.2015.50.

Sign in

Purchase Options

• Subscribe to the journal
• Rent this article ?

A free personal account provides

• Free current issues on The JAMA Network Reader
• Free quizzes on The JAMA Network Challenge
• Commenting and personalized alerts
From The JAMA Network
JAMA Oncology
Editorial  | 
Broad Applicability of Nivolumab in Melanoma Regardless of BRAF Mutation Status
Tara C. Gangadhar, MD; Lynn M. Schuchter, MD
JAMA Oncology
Original Investigation  | 
Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma:  A Pooled Analysis of 4 Clinical Trials
James Larkin, MD, PhD; Christopher D. Lao, MD, MPH; Walter J. Urba, MD, PhD; et al.
JAMA
Viewpoint  | 
Single Molecules Meet Genomics:  Pinpointing Precision Medicine
Xiaoliang Sunney Xie, PhD
JAMA Oncology
Research Letter  | 
Acquired Resistance of EGFR-Mutant Lung Cancer to a T790M-Specific EGFR Inhibitor:  Emergence of a Third Mutation (C797S) in the EGFR Tyrosine Kinase Domain
Helena A. Yu, MD; Shaozhou K. Tian, MD; Alexander E. Drilon, MD; et al.